Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
3.5 monsta
KBIO agreements with Sanofi and Novartis...Since our inception, we have financed our operations primarily through proceeds from the public offerings of our common stock, private placements of our preferred stock, debt financings, interest income earned on cash, and cash equivalents, and marketable securities, borrowings against lines of credit, and receipts from agreements with Sanofi and Novartis. At June 30, 2015, we had cash and cash equivalents and investments of $23.0 million.
CAP is only $9m
Chart is bullish and this was solid as a rock in the big down market
"As of June 30, 2015, KaloBios had cash, cash equivalents and investments totaling $23.2 million". market cap is only $8.7m, and there are only 4m outstanding. 87% ownership!!,float is about $700k. just imagine the potential here.good news/data could send this into the $50m cap and north imo.
Development Program Updates
KB004 Immuno-oncology Program
KB004, the company's monoclonal antibody (mAb) targeting EphA3, is currently in clinical development in the phase 2 expansion portion of an open-label Phase 1/2 study in hematologic malignancies. The Phase 2 portion of the study is currently enrolling two cohorts of up to 20 patients each at the 250mg dose level selected as a result of the Phase 1 dose escalation portion of the study. One cohort consists of patients with myelodysplastic syndrome (MDS), and a second cohort consists of patients with myelofibrosis (MF). Patients in both cohorts must be relapsed-refractory to standard-of-care treatment, and pre-screened to ensure tumor EphA3 expression. As of August 1, 2015, the phase 2 expansion portion of the study has enrolled a total of 8 patients in the MDS cohort and 6 patients in the MF cohort. Based on current enrollment rates, and with several additional clinical sites expected to commence enrollment in the coming months, the company expects enrollment to continue to accelerate. The drug continues to be well tolerated with the most commonly reported side effects being infusion reactions.
KB003 Oncology Program
In July, KaloBios announced that the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug (IND) application for KB003, an anti-GM-CSF mAb, testing in patients with chronic myelomonocytic leukemia (CMML), an orphan oncology indication. As a result, KaloBios is initiating an open-label Phase I study designed to evaluate the safety, pharmacokinetics and clinical activity of KB003 in previously treated CMML patients. The study will consist of an accelerated dose-escalation component starting at 200 mg and escalating up to 600 mg, followed by a cohort expansion of up to 13 additional patients to explore clinical activity at the selected dose level. Site initiation activities are underway, and the company anticipates that enrollment will begin later this year.
"We have made excellent progress in 2015 in strengthening our oncology focus at KaloBios," said Herb Cross, KaloBios' Chief Financial Officer and Interim Chief Executive Officer. "We continue to work to expand our portfolio of oncology programs in clinical development, most notably with the addition of a third oncology indication as a result of the July FDA clearance of our IND for KB003 in CMML. We continue to enroll patients in the KB004 Phase 2 program in MDS and MF, as well as evaluating additional potential oncology indications for KB004 including solid tumors where EphA3 is expressed. With several oncology indications either in development or moving into the clinic, and other potential indications under evaluation, we continue to be excited about the potential of our assets."
Was waiting for a small drop yet may not happen will be watching and waiting for my order
2.26 pm hits,going to 4+ imo and if a good news hits maybe we will have another AQXP.700k float,8m cap,Cash more than twice current market cap.
classic accumulation,the buyer knows there are no many shares available.
im still watching im about to go in
do you see the 15k in bids($2),wont take too much here.
10k buy order 2.1 wont take too much here.accumulation going for a week+ but the buyer buying in small amounts due to the very low and rare float.
Same here.Immediate value is $4 PPS, $16m in cash per last 10q,trading on $8m market value.,there is not much shares available to buy so, any positive news or insiders/institutions buys possibility send this.
4m o/s,87% ownership!!
Noticed that too..some loading going on with this float any pr sky rockets it
I'm liking this one Ash. I'm buying in tomorrow morning
Thats twice within the last 3 days we have seen a spike of 150,000 shares traded over the 30 day average. Does anyone have any details whether it was a block trade or multiples?
looking for employees http://www.kalobios.com/careers/departments
$16m in cash vs $8m cap.very interesting.,there is not much shares available to buy so, any positive news or insiders/institutions buys possibility send this very fast.
Market getting stronger here too....
$KBIO recent news/filings
bullish
charts that are focused on long term growth and are not affected by earnings reports
## source: finance.yahoo.com
Mon, 13 Jul 2015 21:12:24 GMT ~ KALOBIOS PHARMACEUTICALS INC Files SEC form 8-K, Material Modification to Rights of Security Holders, Change in Direc
read full: http://biz.yahoo.com/e/150713/kbio8-k.html
*********************************************************
Mon, 13 Jul 2015 12:11:14 GMT ~ KaloBios Announces Shareholders and Board of Directors Approval of Reverse Stock Split
[at noodls] - SOUTH SAN FRANCISCO, Calif., July 13, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), a monoclonal antibody company focused on developing innovative therapies to benefit patients with ...
read full: http://www.noodls.com/view/3EB97039679F9948E4F50AD622187D0273B3B05F
*********************************************************
Mon, 13 Jul 2015 12:01:00 GMT ~ KaloBios Announces Shareholders and Board of Directors Approval of Reverse Stock Split
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., July 13, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), a monoclonal antibody company focused on developing innovative therapies to benefit patients with ...
read full: http://finance.yahoo.com/news/kalobios-announces-shareholders-board-directors-120100558.html
*********************************************************
Fri, 26 Jun 2015 07:24:01 GMT ~ Edited Transcript of KBIO presentation 23-Jun-15 2:30pm GMT
read full: http://finance.yahoo.com/news/edited-transcript-kbio-presentation-23-072401164.html
*********************************************************
Wed, 17 Jun 2015 18:01:16 GMT ~ KaloBios to Present at the JMP Securities Life Sciences Conference
[at noodls] - SOUTH SAN FRANCISCO, Calif., June 17, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that it will present at the JMP Securities Life Sciences Conference 2015 in New ...
read full: http://www.noodls.com/view/0D186EEFD11605283D1E7BF28F9DE5851FC42F5A
*********************************************************
$KBIO charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$KBIO company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/KBIO/company-info
Ticker: $KBIO
OTC Market Place: Not Available
CIK code: not found
Company name: KaloBios Pharmaceuticals, Inc.
Incorporated In:
Business Description:
$KBIO share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: 4,124,022 a/o Jul 14, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$KBIO extra dd links
Company name: KaloBios Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=KBIO+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=KBIO+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=KBIO+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/KBIO/news - http://finance.yahoo.com/q/h?s=KBIO+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/KBIO/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/KBIO/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=KBIO+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/KBIO
DTCC (dtcc.com): http://search2.dtcc.com/?q=KaloBios+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=KaloBios+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=KaloBios+Pharmaceuticals%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/KBIO
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/KBIO/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/KBIO/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=KBIO&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=KBIO
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/KBIO/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=KBIO+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=KBIO+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=KBIO
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=KBIO
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=KBIO+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/KBIO/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=KBIO+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/KBIO.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=KBIO
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/KBIO/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/KBIO
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/KBIO
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/KBIO:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=KBIO
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=KBIO
$KBIO DD Notes ~ http://www.ddnotesmaker.com/KBIO
dunno. still sitting on support. just taking longer than i wanted
I dnt understand why the selling?
pennant today. kind of a weak pennant but as long as it holds over that base at .56 should be good to go
$KBIO recent news/filings
bullish
## source: finance.yahoo.com
Thu, 28 May 2015 20:38:10 GMT ~ KaloBios Appoints Ronald A. Martell Executive Chairman
[at noodls] - SOUTH SAN FRANCISCO, Calif., May 28, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Ronald A. Martell, to the position of Executive Chairman. Mr. ...
read full: http://www.noodls.com/view/0C49915A17810544556B24F1938E645D10B186FF
*********************************************************
Thu, 28 May 2015 20:01:00 GMT ~ KaloBios Appoints Ronald A. Martell Executive Chairman
[PR Newswire] - SOUTH SAN FRANCISCO, Calif., May 28, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (KBIO) today announced the appointment of Ronald A. Martell, to the position of Executive Chairman. In this new role, he will work directly with the company's senior management team to refine and execute on the strategic plan to transition KaloBios to a focused monoclonal antibody company developing therapeutics for orphan oncology indications with high unmet medical need. Mr. Martell will assume the duties of Board Chairman currently held by Ted W. Love, MD, who will continue to act as lead independent director on the KaloBios Board.
read full: http://finance.yahoo.com/news/kalobios-appoints-ronald-martell-executive-200100295.html
*********************************************************
Thu, 28 May 2015 17:42:00 GMT ~ 5 Stocks Under $10 Triggering Breakout Trades
read full: http://www.thestreet.com/story/13167166/1/5-stocks-under-10-triggering-breakout-trades.html?puc=yahoo&cm_ven=YAHOO
*********************************************************
Tue, 19 May 2015 17:04:23 GMT ~ KALOBIOS PHARMACEUTICALS INC Financials
read full: http://finance.yahoo.com/q/is?s=kbio
*********************************************************
Mon, 11 May 2015 14:37:54 GMT ~ KaloBios Reports First Quarter 2015 Financial Results
[at noodls] - SOUTH SAN FRANCISCO, Calif., May 11, 2015 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today reported its financial results for the first quarter of 2015. Net loss for the quarter ended ...
read full: http://www.noodls.com/view/8D31CCFAAB3A0C85D514BC04949243DD0D69E1B0
*********************************************************
$KBIO charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$KBIO company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/KBIO/company-info
Ticker: $KBIO
OTC Market Place: Not Available
CIK code: not found
Company name: KaloBios Pharmaceuticals, Inc.
Incorporated In:
Business Description:
$KBIO share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$KBIO extra dd links
Company name: KaloBios Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=KBIO+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=KBIO+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=KBIO+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/KBIO/news - http://finance.yahoo.com/q/h?s=KBIO+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/KBIO/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/KBIO/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=KBIO+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/KBIO
DTCC (dtcc.com): http://search2.dtcc.com/?q=KaloBios+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=KaloBios+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=KaloBios+Pharmaceuticals%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/KBIO
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/KBIO/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/KBIO/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=KBIO&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=KBIO
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/KBIO/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=KBIO+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=KBIO+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=KBIO
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=KBIO
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=KBIO+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/KBIO/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=KBIO+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/KBIO.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=KBIO
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/KBIO/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/KBIO/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/KBIO
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/KBIO
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/KBIO:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=KBIO
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=KBIO
$KBIO DD Notes ~ http://www.ddnotesmaker.com/KBIO
I bought a position today @ .58 don't see any news do you?
Nice one, and no posts on this today. weird.
need a pop and the crowd to sell
What does the Kbio chart actually say?
sorry wrong board
Wow, that was helpful, comment on a post from January 8.
Chart says sell
lets hope so looking for that dollar holla! and free up some cash!
should be some news coming out this week
Chart, consolidating after drop few institutions may be adding, cash rich co trading under cash. Pipe seems good going forward
I like the movment but WHY
Company has made no anouncment since it failed it study and at the time they had no plans other than review? They stated that would take till June??
So WHY is it moving??
I don't see a cup and handle, but I can smell this is gonna run hard.
I think it has formed a cup and handle ?
Technical - trading Buy - strong buy !
http://amigobulls.com/stocks/KBIO/technical-charts
Barica Investments Germany
www.barica-investments.com
CEO Bernd Ahne
Bavaria - Munich
Austria - Salzburg
Ilalia - Rome
Giddy-up in from .465 holding for the dollar holler!
KBIO - Strong Buy
Barica Investments - Germany
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43174
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |